Payment overview · 2025
General Payments
$208.63
11 reported records · 5 companies
Healthcare provider profile · identity verified
David Nathaniel Arthur Ryan, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BOUNTIFUL, UT · NPI 1134130131
Verified facts
What the public records show
CMS Open Payments records show David Nathaniel Arthur Ryan, D.O. received $208.63 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.21 | 38.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.38 | 25.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.74 | 16.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.68 | 11.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.62 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.63 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 426 | 129 |
| Losartan Potassium | Losartan Potassium | 424 | 119 |
| Lisinopril | Lisinopril | 406 | 123 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 386 | 97 |
| Metformin Hcl | Metformin Hcl | 336 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 83 |
| Gabapentin | Gabapentin | 271 | 70 |
| Omeprazole | Omeprazole | 269 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 82 |
| Montelukast Sodium | Montelukast Sodium | 206 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 188 | 70 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 170 | 114 |
| Ezetimibe | Ezetimibe | 169 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 50 |
| Trazodone Hcl | Trazodone Hcl | 159 | 47 |
| Meloxicam | Meloxicam | 155 | 61 |
| Famotidine | Famotidine | 154 | 46 |
| Azithromycin | Azithromycin | 150 | 118 |
| Furosemide | Furosemide | 134 | 47 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 133 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 42 |
| Ibuprofen | Ibuprofen | 127 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 43 |
| Eliquis | Apixaban | 112 | 35 |
| Sertraline Hcl | Sertraline Hcl | 104 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 22 |
| Alendronate Sodium | Alendronate Sodium | 102 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 26 |
| Farxiga | Dapagliflozin Propanediol | 99 | 20 |
| Simvastatin | Simvastatin | 98 | 30 |
| Glipizide | Glipizide | 94 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 75 |
| Baclofen | Baclofen | 88 | 25 |
| Cephalexin | Cephalexin | 87 | 60 |
| Methylprednisolone | Methylprednisolone | 82 | 73 |
| Carvedilol | Carvedilol | 77 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 19 |
| Fenofibrate | Fenofibrate | 74 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 16 |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Potassium Chloride | Potassium Chloride | 68 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Glipizide Er | Glipizide | 60 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 56 | 18 |
| Finasteride | Finasteride | 51 | 14 |
| Celecoxib | Celecoxib | 50 | 14 |
| Allopurinol | Allopurinol | 49 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 17 |
| Ozempic | Semaglutide | 47 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 14 |
| Tramadol Hcl | Tramadol Hcl | 38 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 17 |
| Alprazolam | Alprazolam | 36 | 14 |
| Atenolol | Atenolol | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Diazepam | Diazepam | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 11 |
| Amoxicillin | Amoxicillin | 30 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Sucralfate | Sucralfate | 29 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Prednisone | Prednisone | 24 | 20 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 19 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valproic Acid | Valproic Acid | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Jardiance | Empagliflozin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.63 · 11 records | Exact Sciences Corporation | Cologuard Collection Kit, FARXIGA, JARDIANCE, OTEZLA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error